Over the last 7 days, the U.S. market has dropped 2.3%, but it is up 21% over the past year with earnings forecasted to grow by 19% annually. In light of these conditions, identifying stocks with strong fundamentals and growth potential can be key to navigating market fluctuations. Penny stocks, though an older term, still represent a viable investment area; they often involve smaller or newer companies that offer unique growth opportunities at lower price points.

Let's explore several standout options from the results in the screener.

Akebia Therapeutics (AKBA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for kidney disease patients, with a market cap of approximately $292.40 million.

Operations: The company generates $232.40 million in revenue from its segment focused on developing and commercializing innovative therapeutics.

Market Cap: $292.4M

Akebia Therapeutics, with a market cap of US$292.40 million, has been reducing its losses at a significant rate over the past five years and maintains a cash runway exceeding three years due to positive free cash flow. Despite being unprofitable and not expected to achieve profitability soon, Akebia's short-term assets cover both its short- and long-term liabilities. Recent developments include an increase in authorized shares and the strengthening of its intellectual property portfolio through new patents for Vafseo, which is approved for anemia treatment in dialysis patients across 37 countries. However, Akebia faces high debt levels with a net debt to equity ratio considered elevated.

Atea Pharmaceuticals (AVIR)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics for serious viral infections, with a market cap of $351.32 million.

Operations: Atea Pharmaceuticals, Inc. has not reported any specific revenue segments.

Market Cap: $351.32M

Atea Pharmaceuticals, Inc., with a market cap of US$351.32 million, remains pre-revenue but is advancing its antiviral drug pipeline targeting significant unmet medical needs in hepatitis C and E. Recent Phase 1 results for their BEM/RZR regimen show low drug-drug interaction risks, crucial for patients managing multiple medications. The company also showcased promising preclinical data for AT-587 against HEV at the EASL Congress 2026. Despite being unprofitable with increasing losses and no revenue streams yet, Atea has no debt and a seasoned management team, offering potential upside if clinical trials succeed in addressing global health challenges.

Stitch Fix (SFIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Stitch Fix, Inc. operates in the United States, providing clothing and accessories, with a market cap of $535.04 million.

Operations: The company's revenue primarily comes from its online retail segment, which generated $1.33 billion.

Market Cap: $535.04M

Stitch Fix, Inc., with a market cap of US$535.04 million, is navigating challenges typical for penny stocks. Despite being unprofitable with a negative return on equity of -9.49%, the company has reduced losses by 13.2% annually over five years and maintains sufficient cash runway exceeding three years due to positive free cash flow. Recent earnings guidance suggests stable revenue expectations between US$1.346 billion and US$1.351 billion for fiscal 2026, despite ongoing legal issues involving a proposed settlement of US$32 million related to securities class action lawsuits from past stockholders' grievances during 2020-2022.

Taking Advantage

• Explore the 338 names from our US Penny Stocks screener here.
• Interested In Other Possibilities? We've found 9 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.